Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00211419
Other study ID # Double Injection
Secondary ID
Status Completed
Phase Phase 1
First received September 13, 2005
Last updated October 23, 2012

Study information

Verified date September 2005
Source Manhattan Eye, Ear & Throat Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

1. A male or female with evidence of exudative age-related macular degeneration with clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal choroidal neovascularization (CNV) which has not responded to current therapy

2. Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640

3. Patient must be willing and able to comply with the protocol and provide informed consent.

Exclusion Criteria:

1. Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior to the injection procedure. Note: Patients on oral anticoagulant therapy may be considered to participate if the physician responsible for monitoring the anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy prior to each anecortave injection. The attending doctor must notify the principal investigator and this notification will be made part of the source documentation. Anticoagulant therapy may resume either the evening of or the morning after the injection procedure.

2. Patient with known glaucoma or steroid induced ocular hypertension

3. Intraocular pressures of 21 mmHg or greater at time of entry into the study

4. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions

5. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye

6. Patient participating in any other investigational drug study

7. Inability to obtain photographs to document CNV (including difficulty with venous access)

8. Concomitant oral steroids or topical ophthalmic steroid use

9. Sub-Tenon's injection of steroids within the past 6 months

10. Patient with significant liver disease or uremia

11. Patient with known adverse reaction to indocyanine green, iodine, verteporfin, or triamcinolone

12. Patient is pregnant or nursing

13. Age less than 50 years old

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Anecortave Acetate 15 mg

Triamcinolone Acetate 4 mg

Procedure:
Photodynamic Therapy with Verteporfin

Thermal Laser


Locations

Country Name City State
United States Manhattan Eye, Ear & Throat Hospital New York New York

Sponsors (2)

Lead Sponsor Collaborator
Manhattan Eye, Ear & Throat Hospital Alcon Research

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT00058994 - An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD Phase 3
Completed NCT00417846 - Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study) N/A
Completed NCT00051129 - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Recruiting NCT00331253 - Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP). Phase 2